{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T09:23:39Z","timestamp":1760865819006},"reference-count":31,"publisher":"Oxford University Press (OUP)","issue":"17","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2013,9,1]]},"DOI":"10.2146\/ajhp120645","type":"journal-article","created":{"date-parts":[[2013,8,13]],"date-time":"2013-08-13T15:58:26Z","timestamp":1376409506000},"page":"1496-1501","source":"Crossref","is-referenced-by-count":12,"title":["Intravenous acetylcysteine for indications other than acetaminophen overdose"],"prefix":"10.1093","volume":"70","author":[{"given":"Stephanie","family":"Bass","sequence":"first","affiliation":[{"name":"Cleveland Clinic, Cleveland, OH"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nathaniel","family":"Zook","sequence":"additional","affiliation":[{"name":"Aurora St. Luke\u2019s Medical Center, Milwaukee, WI"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","reference":[{"key":"2019041607500415900_b1-0701496","first-page":"265","article-title":"N-acetylcysteine: multiple clinical applications","volume":"80","author":"Millea","year":"2009","journal-title":"Am Fam Physician."},{"key":"2019041607500415900_b2-0701496","doi-asserted-by":"crossref","first-page":"1852","DOI":"10.1056\/NEJM199106273242604","article-title":"Improvement by acetylcysteine of hemodynamics and oxygen transport in fulminant hepatic failure","volume":"324","author":"Harrison","year":"1991","journal-title":"N Engl J Med."},{"key":"2019041607500415900_b3-0701496","volume-title":"Acetadote (acetylcysteine) prescribing information","year":"2008"},{"key":"2019041607500415900_b4-0701496","doi-asserted-by":"crossref","first-page":"1821","DOI":"10.2146\/ajhp060050","article-title":"Comparison of oral and i.v. acetylcysteine in the treatment of acetaminophen poisoning","volume":"63","author":"Kanter","year":"2006","journal-title":"Am J Health-Syst Pharm."},{"key":"2019041607500415900_b5-0701496","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1016\/j.annemergmed.2009.05.010","article-title":"Comparison of the 20-hour intravenous and 72-hour oral acetylcysteine protocols for the treatment of acute acetaminophen poisoning","volume":"54","author":"Yarema","year":"2009","journal-title":"Ann Emerg Med."},{"key":"2019041607500415900_b6-0701496","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1345\/aph.1D209","article-title":"Acetylcysteine treatment for non-acetaminophen-induced acute liver failure","volume":"38","author":"Sklar","year":"2004","journal-title":"Ann Pharmacother."},{"key":"2019041607500415900_b7-0701496","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1002\/lt.21246","article-title":"Safety and efficacy of N-acetylcysteine in children with non-acetaminophen-induced acute liver failure","volume":"14","author":"Kortsalioudaki","year":"2008","journal-title":"Liver Transpl."},{"key":"2019041607500415900_b8-0701496","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1007\/s12072-009-9151-0","article-title":"Role of N-acetylcysteine in adults with non-acetaminophen-induced liver failure in a center without the facility of liver transplantation","volume":"3","author":"Mumtaz","year":"2009","journal-title":"Hepatol Int."},{"key":"2019041607500415900_b9-0701496","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1053\/j.gastro.2009.06.006","article-title":"Intravenous N-acetylcysteine improves transplant-free survival in early stage non-acetaminophen acute liver failure","volume":"137","author":"Lee","year":"2009","journal-title":"Gastroenterology."},{"key":"2019041607500415900_b10-0701496","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1002\/hep.26001","article-title":"Intravenous N-acetylcysteine in pediatric patients with nonacetaminophen acute liver failure: a placebo-controlled clinical trial","volume":"57","author":"Squires","year":"2013","journal-title":"Hepatology."},{"key":"2019041607500415900_b11-0701496","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1002\/hep.23258","article-title":"Alcoholic liver disease","volume":"51","author":"O\u2019Shea","year":"2010","journal-title":"Hepatology."},{"key":"2019041607500415900_b12-0701496","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/0016-5085(78)90401-8","article-title":"Corticosteroid therapy of alcoholic hepatitis","volume":"75","author":"Maddrey","year":"1978","journal-title":"Gastroenterology."},{"key":"2019041607500415900_b13-0701496","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1056\/NEJMoa1101214","article-title":"Glucocorticoids plus N-acetylcysteine in severe alcoholic hepatitis","volume":"365","author":"Nguyen-Khac","year":"2011","journal-title":"N Engl J Med."},{"key":"2019041607500415900_b14-0701496","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1016\/S0016-5085(98)70034-4","article-title":"Selective glutathione depletion of mitochondria by ethanol sensitizes hepatocytes to tumor necrosis factor","volume":"115","author":"Colell","year":"1998","journal-title":"Gastroenterology."},{"key":"2019041607500415900_b15-0701496","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/S0140-6736(05)74933-3","article-title":"Improvement in renal function in hepatorenal syndrome with N-acetylcysteine","volume":"353","author":"Holt","year":"1999","journal-title":"Lancet."},{"key":"2019041607500415900_b16-0701496","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1016\/j.jhep.2005.11.039","article-title":"Antioxidants versus corticosteroids in the treatment of severe alcoholic hepatitis\u2014a randomised clinical trial","volume":"44","author":"Phillips","year":"2006","journal-title":"J Hepatol."},{"key":"2019041607500415900_b17-0701496","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.jhep.2007.03.027","article-title":"A randomized trial of antioxidant therapy alone or with corticosteroids in acute alcoholic hepatitis","volume":"47","author":"Stewart","year":"2007","journal-title":"J Hepatol."},{"key":"2019041607500415900_b18-0701496","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1016\/j.jhep.2010.05.030","article-title":"Enteral nutrition with or without N-acetylcysteine in the treatment of severe acute alcoholic hepatitis: a randomized multicenter controlled trial","volume":"53","author":"Moreno","year":"2010","journal-title":"J Hepatol."},{"key":"2019041607500415900_b19-0701496","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1592\/phco.28.9.1140","article-title":"Contrast medium-induced nephropathy: strategies for prevention","volume":"28","author":"Massicotte","year":"2008","journal-title":"Pharmacotherapy."},{"key":"2019041607500415900_b20-0701496","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1136\/hrt.2004.053579","article-title":"N-acetylcysteine for prevention of radiocontrast induced nephrotoxicity: the importance of dose and route of administration","volume":"91","author":"Shalansky","year":"2005","journal-title":"Heart."},{"key":"2019041607500415900_b21-0701496","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1056\/NEJM200007203430304","article-title":"Prevention of radiographic-contrast-agent-induced reductions in renal function by acetylcysteine","volume":"343","author":"Tepel","year":"2000","journal-title":"N Engl J Med."},{"key":"2019041607500415900_b22-0701496","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/S0735-1097(02)01958-7","article-title":"Acetylcysteine and contrast agent-associated nephrotoxicity","volume":"40","author":"Briguori","year":"2002","journal-title":"J Am Coll Cardiol."},{"key":"2019041607500415900_b23-0701496","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1016\/S0002-9149(01)02243-3","article-title":"Acetylcysteine to prevent angiography-related renal tissue injury (the APART trial)","volume":"89","author":"Diaz-Sandoval","year":"2002","journal-title":"Am J Cardiol."},{"key":"2019041607500415900_b24-0701496","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/j.ehj.2003.11.016","article-title":"Standard vs double dose of N-acetylcysteine to prevent contrast agent associated nephrotoxicity","volume":"25","author":"Briguori","year":"2004","journal-title":"Eur Heart J."},{"key":"2019041607500415900_b25-0701496","doi-asserted-by":"crossref","first-page":"59K","DOI":"10.1016\/j.amjcard.2006.01.024","article-title":"Strategies to reduce the risk of contrast-induced nephropathy","volume":"98","author":"Stacul","year":"2006","journal-title":"Am J Cardiol."},{"key":"2019041607500415900_b26-0701496","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1161\/CIRCULATIONAHA.111.038943","article-title":"Acetylcysteine for prevention of renal outcomes in patients undergoing coronary and peripheral vascular angiography: main results from the randomized Acetylcysteine for Contrast-induced nephropathy Trial (ACT)","volume":"124","author":"Berwanger","year":"2011","journal-title":"Circulation."},{"key":"2019041607500415900_b27-0701496","doi-asserted-by":"crossref","first-page":"2114","DOI":"10.1016\/S0735-1097(03)00487-X","article-title":"A rapid protocol for the prevention of contrast-induced renal dysfunction: the RAPPID study","volume":"41","author":"Baker","year":"2003","journal-title":"J Am Coll Cardiol."},{"key":"2019041607500415900_b28-0701496","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1016\/j.ahj.2004.03.041","article-title":"A randomized controlled trial of intravenous N-acetylcysteine for the prevention of contrast-induced nephropathy after cardiac catheterization: lack of effect","volume":"148","author":"Webb","year":"2004","journal-title":"Am Heart J."},{"key":"2019041607500415900_b29-0701496","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1016\/j.jvs.2004.09.026","article-title":"Prevention of contrast-induced nephropathy in vascular patients undergoing angiography: a randomized controlled trial of intravenous N-acetylcysteine","volume":"40","author":"Rashid","year":"2004","journal-title":"J Vasc Surg."},{"key":"2019041607500415900_b30-0701496","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.ijcard.2006.04.023","article-title":"Intravenous N-acetylcysteine for preventing contrast-induced nephropathy: a randomised trial","volume":"115","author":"Carbonell","year":"2007","journal-title":"Int J Cardiol."},{"key":"2019041607500415900_b31-0701496","doi-asserted-by":"crossref","first-page":"2773","DOI":"10.1056\/NEJMoa054209","article-title":"N-acetylcysteine and contrast-induced nephropathy in primary angioplasty","volume":"354","author":"Marenzi","year":"2006","journal-title":"N Engl J Med."}],"container-title":["American Journal of Health-System Pharmacy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/ajhp\/article-pdf\/70\/17\/1496\/28456265\/ajhp1496.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,7,20]],"date-time":"2019-07-20T18:49:04Z","timestamp":1563648544000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ajhp\/article\/70\/17\/1496\/5112318"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,9,1]]},"references-count":31,"journal-issue":{"issue":"17","published-print":{"date-parts":[[2013,9,1]]}},"URL":"https:\/\/doi.org\/10.2146\/ajhp120645","relation":{},"ISSN":["1079-2082","1535-2900"],"issn-type":[{"value":"1079-2082","type":"print"},{"value":"1535-2900","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2013,9,1]]},"published":{"date-parts":[[2013,9,1]]}}}